FENC
$7.32-0.33 (-4.31%)
Fennec Pharmaceuticals Inc.
Recent News
Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +28.35% and +3.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -7.14% and +81.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
B Riley Reaffirms Fennec's Buy Rating, US$16.00 Price Target After Cipla Settlement
B. Riley reiterated its buy rating on the shares of Fennec Pharmaceuticals (FRX.TO, FENC) and its US
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State
Water Giant With $7 Billion in Revenue Draws $7.5 Million Investment, and Shares Are Surging This Year
This water solutions provider serves both consumers and businesses through recurring sales and a broad portfolio of regional brands.